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Abstract
The	aim	of	this	paper	was	to	review	scientific	evidence	on	the	possible	use	of	the	combined	angiotensin	II	receptor	antagonist	
and	neprilysin	inhibitors	(ARNI)	in	patients	with	right	heart	failure	(RHF)	in	the	course	of	chronic	obstructive	pulmonary	disease	
(COPD).	 It	has	been	proven	that	a  lack	of	neprilysin	or	 its	reduced	expression	in	hypoxia	 leads	to	exacerbation	of	pulmonary	
arterial	remodelling	(PAR)	or	pulmonary	hypertension	(PH)	in	the	mechanism	related	to	the	platelet-derived	growth	factor	(PDGF)	
resulting	in	the	proliferation	and	migration	of	pulmonary	artery	smooth	muscle	cells	and	endothelial-to-mesenchymal	transition.	
Such	action	in	the	course	of	COPD	can	lead	to	RHF,	which	would	signify	noxious	effect	of	this	group	of	drugs.	However,	the	
inhibition	of	neprilysin	also	hinders	natriuretic	peptide	metabolism.	The	representative	of	this	group	—	brain	natriuretic	peptide	
(BNP)	—	acts	as	a vasodilator	and	also	exerts	an	antiproliferative	activity	through	the	cGMP-dependent	protein	kinase	G	pathway.	
Additionally,	it	causes	bronchodilation	by	inducing	the	release	of	acetylcholine	from	bronchial	epithelial	cells.	This	suggests	that	
natriuretic	peptides	may	appear	to	be	a potential	treatment	agent	in	patients	with	cardiac	complications	and	COPD.	Their	effects	
associated	with	the	immunosuppression	capacity	by	reducing	the	release	of	inflammatory	mediators	—	IL-6,	IL-1b,	and	TNF-a	
can	bring	benefits	to	patients	with	acute	lung	injury	caused	by	pulmonary	inflammation	during	COPD	exacerbations.	Considering	
the	potentially	positive	effect	of	natriuretic	peptides	in	this	group	of	patients,	further	research	is	required	in	this	area,	which	can	
provide	strong	scientific	data	demonstrating	the	need	for	introducing	ARNI	drugs	to	the	treatment	of	patients	with	COPD.	
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Introduction
Chronic obstructive pulmonary disease 
(COPD) is an incurable, progressive systemic 
disease affecting more and more people in the 
world. Epidemiological data indicates that in 
Poland COPD is diagnosed in about 10% of Poles 
on the basis of spirometry values greater than or 
equal to 2 according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) guide-
lines [1]. Some reports claim that by 2020, COPD 
will become the third leading cause of death in 
the world after cancer and accidents [2].
This disease is characterised by permanent 
limitation of airflow through the airways and their 
increased inflammatory reaction in response to 
tobacco smoke, biomass-containing fuels, diesel 
exhausts, and infections. The main risk factor 
for the development of COPD is tobacco smoke. 
This factor has been estimated to account for up 
to 80% of cases [1]. COPD induces and coexists 
with numerous diseases.
COPD is not only a lung disease but a mul-
ti-organ and systemic disease as well. Chronic 
respiratory failure affects physical activity, which 
in turn may lead to metabolic problems [3] and 
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an increased risk of embolism [4]. The progres-
sion of COPD results in a significant number of 
complications.
One of the most serious and difficult to 
treat consequences of the disease progression 
is the right heart failure (RHF). This process is 
affected by pulmonary hypertension (PH), which 
arises from chronic hypoxia, destructive effects 
of tobacco smoke and inflammation; these fac-
tors induce the shrinkage of small pulmonary 
arteries and their remodelling. The persistence 
of chronic inflammation over time leads to mor-
phological changes in the pulmonary vessels 
and an increase in vascular resistance, the con-
sequence of which is RHF. Capillary destruction 
is likely to increase this process in the course 
of emphysema, which is also one of the COPD 
complications [1]. 
Therapeutic possibilities in COPD
COPD with numerous comorbidities re-
quires multidirectional treatment and multi-
disciplinary care in order to optimally reduce 
symptoms and the risk of future exacerbations. 
Therapeutic management should therefore be 
thought through, should be consistent, under-
standable for the patient and should include all 
comorbidities as well as the likelihood of their 
development and progression [1]. However, 
polypragmasia must be considered while estab-
lishing the treatment. Apart from administration 
of inhaled drugs, which are the main agents of 
the therapy, the patient should be motivated to 
quit smoking [1]. Physical activity plays a sig-
nificant role in the therapy, and improvement 
in the patient’s condition can eliminate disease 
symptoms or reduce their severity [5]. Properly 
tailored treatment will not only improve respira-
tory efficiency but will also have a positive effect 
on the functioning of the entire patient’s body, 
including cognitive functions. Patients achieve 
beneficial results also through respiratory re-
habilitation [6]. Moreover, adequate nutrition 
exerts an impact on the efficacy of therapy and 
achievement of positive results [1]. Equally 
important and often neglected by practicing 
physicians is patient’s education; knowledge of 
the disease and awareness of its consequences 
improve disease control and increase the chance 
for satisfactory results of therapy. Prophylaxis 
and recommended vaccination against influenza 
and pneumococcal infection are also important 
factors in COPD [1].
ARNI as a novel therapy for heart failure  
in patients with COPD
One of the more recent and more promising 
therapies for heart failure is the administration 
of the combined angiotensin receptor blockers 
(ARBs) — valsartan, with the neprilysin (NEP) 
inhibitor — sacubitril [7]. Sacubitril by inhibiting 
neprilysin prevents the disintegration of natri-
uretic peptides, mainly brain natriuretic peptide 
(BNP) and atrial natriuretic peptide (ANP). NEP 
inhibition leads to an increase in the bioavailabil-
ity of natriuretic peptides, which have a beneficial 
effect on the cardiovascular system in heart fail-
ure — they increase natriuresis and diuresis and 
act as vasodilators. Valsartan and sacubitril exert 
an advantageous action in the prevention of heart 
remodelling [7]. The use of the above-mentioned 
combined substances may have a very beneficial 
pleiotropic effect on the circulatory system of 
patients, arising from the multidirectional action 
of this drug. Valsartan has been shown to suppress 
myocardial remodelling by inhibiting the guanine 
nucleotide-binding protein family, while sacubi-
tril prevents myocardial cell death by inhibiting 
phosphatase and tensin homologue (PTEN) [7]. 
The additive effect of these substances causes the 
reduction in the left ventricular extracellular ma-
trix remodelling (LVEMR). [7] Increasing the con-
centration of natriuretic peptides leads to a drop 
in arterial blood pressure due to the inhibition of 
renin secretion and subsequent blocking of the 
renin-angiotensin-aldosterone system.
The use of this new group of drugs in RHF in 
the course of COPD has been evidenced by scarce 
scientific data, which indicates the need for fur-
ther research. Only a few studies combine nepri-
lysin inhibitors with pulmonary hypertension and 
RHF. These works have shown efficacy of using 
neprilysin inhibitors in reducing pulmonary hy-
pertension (PH) and impeding RHF progression, 
which was associated with the inhibition of ANP 
metabolism [8–10]. However, the studies were 
carried out in the 1990s only on animal models. 
This encouraged the authors of the present study 
to perform a detailed analysis of the role of natri-
uretic peptides and neprilysin in PH, COPD and 
RHF. The purpose of the analysis was to obtain 
the information on potential benefits and side 
effects of using neprilysin inhibitors or natriuretic 
peptides in the above-mentioned diseases.
It is worth mentioning that only after con-
ducting the PARADIGM-HF clinical trial, a new 
group of drugs, the angiotensin II receptor blocker 
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neprilysin inhibitor (ARNI), was introduced to 
the recommendations for the treatment of heart 
failure with reduced ejection fraction (HfrEF) 
according to the American College of Cardiology 
(ACC), the American Heart Association (AHA), 
the Heart Failure Society of America (HFSA), and 
the European Society of Cardiology (ESC) [11]. 
Sacubitril alone has become the object of interest 
for many researchers and the following extensive 
research studies have been undertaken: PARA-
MOUNT and PARAGON trials on the application 
of ARNI in heart failure with preserved ejection 
fraction (HFpEF); LIFE, PIONIER-HF in HFrEF; 
or PARADISE-MI in the secondary prevention of 
infarction [11].
Neprilysin as an intra-membrane 
metalloproteinase 
The therapeutic effect of sacubitril is asso-
ciated with an increase in the concentration of 
natriuretic peptides. To achieve this effect, it is 
necessary to inhibit neprilysin (neutral endopep-
tidase, NEP, CD10), which is an intra-membrane 
metalloproteinase located on chromosome 3q 
25.1-q25.2 [12] involved in the metabolism of 
many proteins, among others, substance P, bra-
dykinin, cholecystokinin [13, 14] or endothelin. 
This protein also demonstrates a wide expression 
in the body — it has been identified, among oth-
ers, in the lungs [15], prostate gland [16], kidneys 
[17], and brain [18]. In the light of the above sci-
entific data, we have put forward the hypothesis 
that the inhibition of such a  thorough enzyme 
will not remain completely neutral for cardiac 
performance in patients with COPD. 
Neprilysin-dependent vascular remodelling 
Decreased expression of NEP or lack of this 
enzyme have been associated with pulmonary 
vascular remodelling in response to chronic 
hypoxia [19]. In addition, NEP expression was 
reduced in the lungs of COPD patients [20], which 
may possibly exacerbate pulmonary vascular re-
modeling in COPD [20]. COPD often leads to PH 
[21, 22], which is connected with chronic hypox-
ia, noxious effects of tobacco smoke, free radicals 
and inflammatory mediators, such as IL-6 [21–24]. 
In the course of PH, pulmonary vascular remodel-
ling arises through proliferation and migration of 
pulmonary artery smooth muscle cells (PASMCs) 
[19, 20, 23, 25–27] and endothelial-to- mesenchy-
mal transition (EndoMT) [28]. Ultimately, this 
hypertension can lead to RHF [22]. Severe PH is 
a relatively rare complication of COPD [21, 29], 
however, it is associated with a worse prognosis 
and an increased risk of death [21]. 
The molecular basis of these mechanisms has 
not been fully understood. The platelet-derived 
growth factor (PDGF) and receptors for PDGF 
(PDGFR) play an important role in the pulmonary 
vascular remodelling and PH [27, 30]. Stimula-
tion of PDGFR and elevated PDGF concentration 
lead to increased proliferation and migration of 
PASMCs [25], and induce EndoMT [28]. Inter-
estingly, the decrease in the amount or total ab-
sence of NEP in PASMCs was associated with an 
increased amount of PDGF and PDGFR [25, 28]. 
The reason for this is the excessive activation of 
the cytoplasmic Src kinase and phosphate and 
tensin homologue (PTEN) phosphorylation due to 
the reduced amount of neprilysin, which finally 
leads to PDGFR activation [25, 31]. Moreover, in 
the absence of NEP, the concentration of its sub-
strates, such as endothelin 1 (ET-1) and fibroblast 
growth factor (FGF-2) significantly elevating the 
PDGF-induced migration and proliferation [25], is 
increased. Additionally, ET-1 as a strong vasocon-
strictor plays a significant role in PH [32]. In re-
sponse to hypoxia, a decreased NEP concentration 
[28] and increased level of PDGF as well as trans-
forming growth factor b1 (TGF-b1), with a positive 
regulation observed between them, were stated in 
pulmonary arterial endothelial cells (PAECs). This 
state induced EndoMT [28]. Despite numerous 
scientific data demonstrating the negative impact 
of TGF-b1 in hypertension [33, 34] and pulmonary 
vascular remodelling [35], there is scientific 
evidence linking the excessive expression of 
TGF-b type II receptor with antiproliferative 
activity in the pulmonary vessels [36]. This can 
play a  protective role in the development of 
pulmonary hypertension occurring in the final 
stage of severe COPD. Neprilysin in an animal 
model inhibited hypoxia-induced EndoMT and 
decreased PDGF and TGF-b1 levels in PAECs; and 
the addition of soluble small interfering siRNA 
to neprilysin (si-NEP) under normoxic conditions 
induced EndoMT [28]. It should be remembered 
that PAR is an extremely complex process in 
which a whole range of other growth factors and 
inflammatory agents are included, however with-
out PDGF or NEP involvement [30].
The experimental model showed that the loss 
of NEP did not result in considerable changes in 
the respiratory and circulatory system under nor-
moxic conditions [19]. Neuroendocrine cell (NEC) 
hyperplasia was the only change in this study [19]. 
This hyperplasia was also obtained while admin-
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Figure 1. Molecular	mechanisms	of	pulmonary	artery	remodelling	and	
pulmonary	hypertension
istering NEP inhibitors [37]. In some works, the 
pulmonary neuroendocrine cell hyperplasia has 
been associated with PH [19, 38, 39]. NECs are 
responsible for the secretion of such substances 
as ET-1, serotonin (5-HT) or substance P, whose 
concentration was significantly increased in NEC 
hyperplasia in the absence of NEP [19]. Other 
papers indicated the potentially positive effect 
of neprilysin inhibitors in PH and PAR [9, 10], 
and one study [19] showed a slight difference 
in right ventricle (RV) hypertrophy in hypoxia: 
NEP-free mice had a smaller RV hypertrophy than 
mice with NEP.
The cited studies were carried out on small 
test groups (4 mice) [19], therefore it is difficult to 
draw clear conclusions on the effect of neprilysin 
in COPD.
The role and expression of NEP in other diseases
In small-cell lung cancer, a  decreased 
expression of neprilysin occurs which hydroly-
ses, among others, bombesin-like peptides [40] 
that can function as autocrine growth factors 
and serve as a suppressor in this tumour [41]. 
This suggests that the inhibition of this enzyme 
may cause a faster progression of this cancer. 
It is also worth mentioning that cigarette smo-
king is one of the reasons for decreasing the 
activity of neprilysin in the lungs through the 
free radical-dependent mechanism [40]. Ciga-
rette smoking increases the risk of developing 
COPD and small-cell lung cancer, while in the 
prostate gland, the NEP expression is positi-
vely regulated by androgens. In the advanced 
stage of prostate cancer, this mechanism is lost, 
which leads to the reduced expression of this 
metalloproteinase [42]. Moreover, the decrease 
in this enzyme was also observed in clear-cell 
and chromophobe renal-cell carcinoma, which 
is associated with the loss of the antitumour 
action of vasoactive intestinal peptide (VIP) 
[43]. In cervical [44] and breast cancer [45, 46], 
anti-progressive action of neprilysin was also 
demonstrated. 
The involvement of neprilysin in beta-amy-
loid hydrolysis is also known [47]. Deposits of 
beta-amyloid may cause Alzheimer’s disease. This 
shows that the effect of ARNI may influence not 
only the lungs but also may act in a systemic way, 
and in the case of patients at high risk of the abo-
ve-mentioned diseases may have a noxious im-
pact accelerating the development of the disease.
Natriuretic peptides as novel therapeutic 
possibilities in patients with COPD 
Structure of natriuretic peptides 
Natriuretic peptides are a group of proteins 
synthesised and secreted mainly by the heart of 
mammals [48]. Atrial natriuretic peptide (ANP) 
is stored in atrial cardiomyocytes in the form 
of proANP (1-126), which is released into the 
blood and digested by corin into biological-
ly active ANP (1-28) and inactive ANP (1-98) 
[49]. The main stimulant of ANP secretion is 
volume overload of the atria caused mainly by 
high venous pressure. Other factors causing the 
increase in ANP secretion are the following: 
tachycardia, endothelin, vasopressin, catechol-
amines, hypoxia, increase in osmolarity, thyroid 
hormones, glucocorticoids, TNFa and other in-
flammatory cytokines [49, 50]. Brain natriuretic 
peptide (BNP) is synthesised mainly in cardiac 
ventricular cardiomyocytes. Due to the action 
of corin on proBNP (1-108), biologically active 
BNP (1-32) and inactive NT-proBNP are formed. 
Unlike ANP, biologically active BNP is released 
into the bloodstream immediately after synthe-
sis, although small amounts can be stored in 
the atrial granules and ventricular tissue [49]. 
In a healthy human, the concentration of this 
peptide is very small, 0.5–30 pg/ml [51], howev-
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Figure 2. Role	of	the	natriuretic	peptides
er, in patients with chronic heart failure, it can 
be significantly increased even by > 500 pg/ml 
[52, 53]. C-type natriuretic peptide (CNP) occurs 
in two biologically active forms, CNP-53 and 
CNP-22, and is secreted mainly by the vascular 
endothelium. The stimulation of CNP secretion 
is primarily caused by the transforming growth 
factor b (TGF-b), and also by tumour necrotic 
factor (TNF), interleukin-1 (Il-1), and fibroblast 
growth factor-2 (FGF-2) [52].
Mechanism of action and elimination  
of natriuretic peptides
So far, three natriuretic peptide receptors, 
NPR-A, NPR-B, NPR-C, have been known. The 
first two belong to the transmembrane proteins 
from the family of receptors coupled to gua-
nylate cyclase [48]. The biological activity of 
ANP and BNP is based on the interaction with 
the transmembrane NPR-A receptor, which leads 
to the conversion of guanosine triphosphate 
(GTP) into cyclic guanosine monophosphate 
(cGMP). This causes the activation of cGMP-de-
pendent protein kinases, which results in the 
physiological effect of natriuretic peptides 
[48, 54, 55]. The ANP/NPR-A  system is re-
sponsible for the decrease in heart overload 
by reducing vascular wall tension, stimulating 
natriuresis and diuresis and inhibiting the re-
nin-angiotensin-aldosterone pathway and the 
growth of cardiomyocytes [54]. CNP affects 
NPR-B, and similarly to NPR-A, its activation 
causes the increase in cGMP. The CNP/NPR-B 
system is responsible for vasodilation and anti-
proliferative effect on vascular smooth muscles 
as well as the regulation of the growth of long 
bones and vertebral bodies [56]. 
The removal of natriuretic peptides takes 
place through binding to NPR-C followed by their 
enzymatic lysosomal degradation, neprilysin 
action, and renal excretion [48].
Effect of natriuretic peptides on the respiratory 
system in healthy people and patients with COPD
Natriuretic peptides are produced in a large 
amount and secreted by the bronchial epithelium, 
pulmonary alveolar epithelium, and Clara cells 
[57]. The degradation of these peptides also oc-
curs to a large extent in the lungs [58].
Vasodilation and antiproliferative activity 
Numerous studies have shown that the con-
centration of ANP and BNP significantly increases 
in PH [58, 59], suggesting their crucial role in the 
regulation of the pulmonary circulation. In COPD 
patients, pulmonary hypertension is associated 
with vasoconstriction caused by chronic hypoxia 
[60]. In patients suffering from chronic obstruc-
tive pulmonary disease, BNP levels are often 
elevated especially with concomitant left hair fail-
ure (LHF), PAR and right heart remodelling [61] 
— these are diseases that often accompany COPD. 
In experiments on mice with pulmonary hyper-
tension induced by chronic hypoxia, after admin-
istration of BNP (1.4 μg/min), a decrease in sys-
tolic pressure in the right ventricle and its mass 
was observed as compared to the control group. 
This effect was associated with reduced pulmo-
nary vascular resistance induced by BNP [62]. 
Another study demonstrated the antiproliferative 
effect of BNP on PASMCs. It has been proven that 
BNP inhibits the proliferation and migration of 
PASMCs induced by angiotensin II. These effects 
are potentially mediated by decreased calcium 
influx, reduced ROS production by Nox1 and 
mitochondria, and down-regulation of MAPK and 
Akt signal transduction, through the cGMP/PKG 
pathway [63]. In COPD patients with secondary 
hypertension induced by hypoxia following 
a synthetic human ANP infusion, a decrease in 
systemic and pulmonary arterial pressure was 
observed, resulting in an increase in cardiac 
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output (CO) with the unchanged heart rate and 
preload. In addition, aldosterone levels decreased 
in these patients [60]. In another study, ANP and 
BNP were found to cause dose-dependent vasodi-
lation of pulmonary vessels in patients with cor 
pulmonale [64].
Bronchodilation
For many years, scientific studies have been 
focused on the impact of natriuretic peptides on 
bronchial obstruction. The research performed on 
animals has proven their bronchodilatory activity. 
Unfortunately, there are few studies confirming 
the effect of natriuretic peptides on human bron-
chospasm. However, it has been evidenced that 
administration of nesiritide (recombinant human 
BNP) resulted in significant bronchodilation in 
asthmatic patients suggesting that this substance 
has a beneficial effect on the respiratory tract and 
may be used as an additional treatment in patients 
with acute exacerbations of asthma resistant to 
standard treatment [65]. Unfortunately, there are 
no such studies concerning the effect of nesiritide 
on COPD patients. The bronchodilator activity of 
BNP is most likely associated with the activation 
of the NPR-A receptor located on the respiratory 
endothelium, which in consequence causes the 
alveolar release of very low concentrations of 
acetylcholine from the bronchial epithelial cells. 
The picomolar concentrations of acetylcholine 
activate the postsynaptic M2 muscarinic recep-
tors located on airway smooth muscle (ASM) 
cells. The activated M2 receptor modulates the 
inducible nitric oxide synthase (iNOS) gene and 
protein expression, causing an increase in ni-
tric oxide (NO) levels in ASM and activation of 
NO/cGMP signalling, which results in bronchial 
relaxation [66]. There are some studies on the use 
of inhaled natriuretic peptides. It has been proven 
that ANP inhaled by asthma patients causes bron-
chodilation, however, this effect lasts for a short 
time, as it is rapidly metabolised by neprilysin. 
The addition of a neutral endopeptidase inhibitor 
to ANP resulted in prolongation of bronchodila-
tion time, however, it was still shorter compared 
to salbutamol [67]. On the other hand, there are 
some studies which demonstrate the beneficial 
effect of neutral endopeptidase on the respira-
tory tract. Neprilysin plays a significant role in 
the degradation of neuropeptides in the airways 
and therefore participates in the regulation of 
bronchial tonus in animals and humans. NEP is 
responsible for inactivating almost 90% of strong 
tachykinins that selectively bind to substance P 
and are responsible for bronchoconstriction [68]. 
Therefore, there are contradictory results as re-
gards the therapeutic application of endopepti-
dase inhibitors to enhance and prolong the action 
of natriuretic peptides. The NPR agonists are an 
alternative. PL-3994 — a strong selective NPR 
agonist, resistant to NEP action, causes relaxation 
of smooth muscles of guinea pig and human respi-
ratory tract. It also exerts a longer effect compared 
to ANP, which suggests its potential benefits in 
patients with asthma [69] and other obstructive 
pulmonary diseases. The above studies confirm 
that natriuretic peptides may serve as additional 
treatment of patients suffering from asthma or 
COPD with accompanying cardiac complications. 
BNP combined with existing bronchodilators 
might be an additional drug in the therapy of pa-
tients refractory to standard treatment. However, 
further research is needed in this area.
Immunosuppressive activity
Natriuretic peptides also affect the immune 
system. The ANP/GC-A/cGMP-dependent signal-
ling pathway has been found to act suppressively 
on the proinflammatory transcription factors, 
nuclear factor-kappaB (NF-kB) and activating 
protein-1 (AP-1), in cells activated by bacterial 
lipopolysaccharide (LPS), thus reducing the re-
lease of inflammatory mediators, i.e. IL-1b, IL-6 
or TNF-a [54]. Moreover, ANP has been shown 
to attenuate the induction of E-selectin by LPS 
in the in vitro study and weakens the penetration 
of inflammatory cells in acute lung injury. This 
suggests that ANP may be an additional drug 
used in the treatment of acute lung injury in the 
course of pneumonia or acute respiratory distress 
syndrome (ARDS) [70]. A very interesting finding 
shows the relationship between CNP and the bio-
film produced by Pseudomonas aeruginosa. One 
of the studies demonstrated that eukaryotic CNP 
reacted with bacterial AmiC resulting in a slight 
increase in virulence and a decrease in the for-
mation of Pseudomonas aeruginosa biofilm. Thus, 
a  thorough analysis of the CNP activity might 
contribute to the discovery of new therapeutic 
methods against Pseudomonas aeruginosa [57, 71] 
— a  frequent pathogen in patients with cystic 
fibrosis or COPD.
Oral natriuretic peptides
The synthesis of oral natriuretic peptides 
is associated with many difficulties. First of all, 
human NPs have a short half-life (ANP — 3.1 min, 
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BNP — 22 min [48]) and are rapidly metabolised 
and removed by the human body. Therefore, nesi-
ritide — recombinant BNP — used in the treatment 
of chronic heart failure, is applied in continuous 
intravenous infusion [72]. For a long time, the syn-
thesis of oral natriuretic peptides has been a great 
challenge for scientists. The digestive enzymes 
found in the stomach and small intestine as well 
as the ineffective transport across the intestinal 
epithelium proved to be powerful barriers [73]. 
However, for a  few years, scientists have been 
publishing satisfactory effects of the synthesis 
of oral NPs [74]. It has been proven that the use 
of short amphiphilic oligomers covalently linked 
to human BNP (hBNP) prolongs the biological 
activity of BNP and causes a significant decrease 
in mean arterial pressure (MAP) in dogs [73]. 
However, there are no reports on the effect of oral 
natriuretic peptides on pulmonary pressure — 
further research is needed in this area.
Conclusions
In the absence of NEP or its decreased ex-
pression under hypoxia conditions, PAR and PH 
increase, which in the course of COPD leads to 
RHF. This relationship may indicate a possible 
exacerbation of symptoms when ARNI is used in 
patients with RHF in the course of COPD. Interest-
ingly, the therapeutic effect of sacubitril on myo-
cardial remodelling and the detrimental effect of 
reduced expression of NEP in hypoxia based on 
the severity of PAR depends on the inhibition of 
PTEN, which may suggest different mechanisms 
of pulmonary vessels and heart remodelling. 
However, the efficacy of ARNI in HFrEF is 
associated with an increase in the activity of 
natriuretic peptides and in particular BNP. The 
vasodilatory and antiproliferative activity of 
these peptides on pulmonary vessels is known. 
In addition, they reduce the RV overload. There 
is evidence that their use could contribute to 
the potential benefits for COPD patients with 
accompanying cardiac complications induced 
by PH. The ambiguity of scientific data on NEP 
and natriuretic peptides regarding their effect 
on PAR and PH and their depletion when using 
NEP inhibitors in RHF encourages researchers 
to perform further investigation in this field. 
Increasing the activity of natriuretic peptides 
may additionally bring benefits to patients 
with COPD and acute lung injury caused by 
sudden pulmonary inflammation (exacerbation) 
due to the immunosuppressive action of these 
peptides.
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